Eosinophilia overview: Difference between revisions

Jump to navigation Jump to search
added information on steroids and other agents effective in hypereosinophilia
WikiBot (talk | contribs)
m Changes made per Mahshid's request
 
(5 intermediate revisions by one other user not shown)
Line 4: Line 4:


==Overview==
==Overview==
Eosinophilia refers to elevated eosinophils in the peripheral blood.  It is important to remember that eosinophilia is a ''symptom'', not a disease. Eosinophilia can be a manifestation of a variety of different disease processes, including neoplastic, infectious, allergic, and idiopathic processes.  When the eosinophil count is markedly elevated and the patient has symptoms attributable to the eosinophils (and not explained by the underlying condition, if any), it is referred to as a [[hypereosinophilic syndrome]].
Eosinophilia refers to elevated eosinophils in the peripheral blood.  It is important to remember that eosinophilia is a ''symptom'', not a disease. Eosinophilia can be a manifestation of a variety of different disease processes, including neoplastic, infectious, allergic, and idiopathic processes.   
 
When the eosinophil count is markedly elevated and the patient has symptoms attributable to the eosinophils (and not explained by the underlying condition, if any), it is referred to as a [[hypereosinophilic syndrome]]. <ref name=":3">National Institute of Allergy and Infectious Disease, Hypereosinophilic Syndrome.  http://www.niaid.nih.gov/topics/EosinophilicDisorders/Pages/Hyper.aspx</ref> Most patients with eosinophilia do not have a hypereosinophilic syndrome.


==Historical Perspective==
==Historical Perspective==
*As mentioned above, eosinophilia is not a unified disease entity, but rather a manifestation of many different disease processes.
*As mentioned above, eosinophilia is not a unified disease entity, but rather a manifestation of many different disease processes.
*The [[eosinophil]] itself was discovered in 1879 <ref>Kay AB. The early history of the eosinophil. Clin Exp Allergy. 2015 Mar;45(3):575-82.</ref> as a granulocytic cell that stained with the red dye eosin.  [[Granulocyte|Granulocytes]] in general were described several decades earlier.
*The [[eosinophil]] itself was discovered in 1879 <ref>Kay AB. The early history of the eosinophil. Clin Exp Allergy. 2015 Mar;45(3):575-82.</ref> as a granulocytic cell that stained with the red dye eosin.  [[Granulocyte|Granulocytes]] in general were described several decades earlier.
*The hypereosinophilic syndrome was first described in 1968. <ref name=":2" />
   
   
==Classification==
==Classification==
*Major disease categories that can cause eosinophilia:
*Major disease categories that can cause eosinophilia: <ref name=":2">Brito-Babapulle. The Eosinophilias including the Hypereosinophilic Syndrome.  British Journal of Hematology (2003) 121(3):203-223.  </ref>
*Allergy/Atopy  
*Allergy/Atopy  
*Infections
*Infections
**Parasitic
**Parasitic: particularly associated with helminths, most protozoan parasites do not cause eosinophilia ([[Toxoplasma]] is an exception)
**Certain fungal organisms (Coccidiomycosis, Aspergillus)
**Certain fungal organisms: Coccidiomycosis
**Viral (HIV, HTLV, Herpes)
*Malignancies
*Malignancies
**Hematologic (primary eosinophil neoplasia, B and T cell [[Lymphoma|lymphomas]], [[Chronic myelogenous leukemia|CML]])
**Hematologic: primary eosinophil neoplasia, B and T cell [[Lymphoma|lymphomas]], [[Chronic myelogenous leukemia|CML]], [[Hodgkin's lymphoma|Hodgkin's Lymphoma]]
**Solid tumors (esp GI malignancies)
**Solid tumors: breast, lung
*[[Myelodysplastic syndrome|Myelodysplastic]] and [[Myeloproliferative disease|myeloproliferative]] disorders
*[[Mastocytosis|Systemic Mastocytosis]]
*[[Addison's disease|Addison's Disease]]
*[[Addison's disease|Addison's Disease]]
*Drug Reactions ([[DRESS syndrome|DRESS]])
*Drug Reactions ([[DRESS syndrome|DRESS]])
Line 28: Line 34:
   
   
==Causes==
==Causes==
* Eosinophilia can be caused  
* Eosinophilia can be caused by numerous different processes listed above. 
   
   
==Differentiating eosinophilia from other Diseases==
==Differentiating eosinophilia from other Diseases==
Line 34: Line 40:
==Epidemiology and Demographics==
==Epidemiology and Demographics==
* Eosinophilia is not a specific disease entity, epidemiologic numbers are availble for major causes of eosinophilia
* Eosinophilia is not a specific disease entity, epidemiologic numbers are availble for major causes of eosinophilia
* Hypereosinophilic syndromes are
* [[Hypereosinophilic syndrome|Hypereosinophilic syndromes]] are extremely rare, estimated at 0.36 to 6.3 people per 100000 in the US. <ref name=":3" /> Adults are most commonly affected, however children and the elderly can be affected as well.
   
   
==Risk Factors==
==Risk Factors==
Line 43: Line 49:
*The diseases eosinophilia can be associated with have a wide range of natural histories and prognoses.  
*The diseases eosinophilia can be associated with have a wide range of natural histories and prognoses.  
*An asthmatic patient with eosinophilia has a very different prognosis than a cancer patient with eosinophilia  
*An asthmatic patient with eosinophilia has a very different prognosis than a cancer patient with eosinophilia  
*Hypereosinophilic syndromes have a poor prognosis and high mortality, mostly from the cardiac effects of hypereosinophilia
   
   
== Diagnosis ==
== Diagnosis ==
===Diagnostic Criteria===
===Diagnostic Criteria===
*The diagnosis of eosinophilia is made when the peripheral blood eosinophil count is greater than 500 cells/microL.
*The diagnosis of eosinophilia is made when the peripheral blood eosinophil count is greater than 500 cells/microL.
*Hypereosinophilic syndrome usually has eosinphil counts greater than 1500 cells/microL.  Hypereosinophilic syndrome also requires the presence of organ dysfunction that is caused by the eosinophils and cannot be explained by another disease process <ref name=":0">Cogan and Roufosse.  Clinical Management of the Hypereosinophilic Syndromes.  Expert Reviews in Hematology 5(3) 275-290 (2012).</ref>.
*Hypereosinophilic syndrome usually has eosinphil counts greater than 1500 cells/microL.  Hypereosinophilic syndrome also requires the presence of organ dysfunction that is caused by the eosinophils and cannot be explained by another disease process <ref name=":3" /><ref name=":0">Cogan and Roufosse.  Clinical Management of the Hypereosinophilic Syndromes.  Expert Reviews in Hematology 5(3) 275-290 (2012).</ref>.
=== Symptoms ===
=== Symptoms ===
*Symptoms seen in eosinophilia are highly variable and reflect the underlying disease.
*Symptoms seen in eosinophilia are highly variable and reflect the underlying disease.
*Hypereosinophilia can cause symptoms due to the release of destructive compounds from eosinophils. <ref name=":0" /> Symptoms attributable to the elevated eosinophil count include:
*Hypereosinophilia can cause symptoms due to the release of destructive compounds from eosinophils. <ref name=":3" /><ref name=":2" /><ref name=":0" /> Symptoms attributable to the elevated eosinophil count include:
**Dermatologic manifestations insluding rash, urticaria
**Dermatologic manifestations insluding rash, urticaria
**Muscle and joint pains
**Heart failure and endocardial fibrosis
**Heart failure and endocardial fibrosis
**Cough and shortness of breath
**Cough and shortness of breath
**Thrombotic and embolic events
**Thrombotic and embolic events
**Encephalopathy
**Encephalopathy or neuropsychiatric disturbances
**Peripheral neuropathies
**Peripheral neuropathies
**Abdominal pain, nausea/vomiting, diarrhea, weight loss
**Abdominal pain, nausea/vomiting, diarrhea, weight loss
Line 75: Line 83:
== Treatment ==
== Treatment ==
=== Medical Therapy ===
=== Medical Therapy ===
*Medical treatment for eosinophilia should be directed at the underlying cause (for example treating parasitic infection).
*Medical treatment for eosinophilia should be directed at the underlying cause (for example treating parasitic infection or malignancy).
*Eosinophilia without evidence of organ dysfunction may be observed with monitoring for evidence of organ involvement.
*Eosinophilia without evidence of organ dysfunction may be observed with monitoring for evidence of organ involvement.
*Treatment of hypereosinophilic syndrome has a number of options including [[corticosteroids]], [[hydroxyurea]], [[interferon-alpha]], [[imatinib]] and other tyrosine kinase inhibitors, IL-5 antibodies, and other cytotoxic and immunomodulatory agents. <ref name=":0" /> <ref name=":1">Ogbogu et al. Hypereosinophilic syndrome: A multicenter, retrospective analysis of clinical characteristics and response to therapy.  Journal of Allergy and Clinical Immunology (2009) 124(6):1319–1325</ref>
*Treatment of hypereosinophilic syndrome has a number of options including [[corticosteroids]], [[hydroxyurea]], [[interferon-alpha]], [[imatinib]] and other tyrosine kinase inhibitors, IL-5 antibodies, and other cytotoxic and immunomodulatory agents. <ref name=":3" /><ref name=":0" /> <ref name=":1">Ogbogu et al. Hypereosinophilic syndrome: A multicenter, retrospective analysis of clinical characteristics and response to therapy.  Journal of Allergy and Clinical Immunology (2009) 124(6):1319–1325</ref>
*Corticosteroids are commonly used as first line therapy. They are able to produce a rapid decrease in eosinophil counts, which is valuable if there is already evidence of organ dysfunction related to high eosinophil levels. <ref name=":0" />
 
**0.5-1mg/kg/kday of prednisone (or the equivalent dose of another steroids) is the recommneded starting dose.  Patients with non-severe disease manifestations can start with lower doses <ref name=":0" />
**Steroids are tapered over time, with second line agents added if needed to maintain control.
**In one study, corticosteroids were able to induce remission in 85% of patients at 1 month <ref name=":1" />
*Hydroxyurea is the most commonly used second-line agent for hypereosinophilic syndrome.  Typical dose range is 500mg-2g per day.  Hydroxyurea acts at the level of the bone marrow to reduce production of new eosinophilis. <ref name=":0" /> As such it is not suitable if a rapid lowering in eosinophil levels is needed.  Hydroxyurea is not usually used alone, it is most often used as an additional steroid-sparing agents.
*[[Interferon-alpha]] is also a second-line, steroid sparing agent.  Use of this agent is limited by its toxicities.  Interferon-alpha also has activity on lymphocytes, so it may be particularly effective in eosinophilia secondary to lymphocytic malignancies. <ref name=":0" />
*[[Imatinib]] and related TKIs have shown promise in treating [[chronic eosinophilic leukemia]] due to similar molecular re-arrangements as CML. <ref name=":0" /> <ref>Pardanani et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders.  Blood 2003 101:3391-3397.</ref> This family of TKIs is very well tolerated.  These drugs are most effective in patients who have the FIP1L1-PDGFRA rearrangement. <ref name=":1" />
*Anti-IL5 antibody [[mepolizumab]] has shown potential to rapidly reduce eosinophil counts in trials and reduce the need for corticosteroids, however this agent is still investigational. <ref>Rothenberg et al. Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab.  NEJM 2008; 358:1215-1228</ref>
*Other cytotoxic agents have been used in isolated cases, but lack strong evidence
*In severe cases refractory to other therapy, stem cell transplant may be considered
=== Surgery ===
=== Surgery ===
*Surgery may be part of the treatment for certain causes of eosinophilia, such as solid organ malignancies.  However most conditions associated with eosinophilia are not treated surgically.
*Surgery may be part of the treatment for certain causes of eosinophilia, such as solid organ malignancies.  However most conditions associated with eosinophilia are not treated surgically.
Line 101: Line 99:


[[Category:Hematology]]
[[Category:Hematology]]
[[Category:Infectious disease]]

Latest revision as of 17:41, 18 September 2017

Eosinophilia Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Eosinophilia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X-Ray

CT

MRI

Other imaging findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Eosinophilia overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Eosinophilia overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Eosinophilia overview

CDC on Eosinophilia overview

Eosinophilia overview in the news

Blogs on Eosinophilia overview

Directions to Hospitals Treating Eosinophilia

Risk calculators and risk factors for Eosinophilia overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: George Leef MD

Overview

Eosinophilia refers to elevated eosinophils in the peripheral blood. It is important to remember that eosinophilia is a symptom, not a disease. Eosinophilia can be a manifestation of a variety of different disease processes, including neoplastic, infectious, allergic, and idiopathic processes.

When the eosinophil count is markedly elevated and the patient has symptoms attributable to the eosinophils (and not explained by the underlying condition, if any), it is referred to as a hypereosinophilic syndrome. [1] Most patients with eosinophilia do not have a hypereosinophilic syndrome.

Historical Perspective

  • As mentioned above, eosinophilia is not a unified disease entity, but rather a manifestation of many different disease processes.
  • The eosinophil itself was discovered in 1879 [2] as a granulocytic cell that stained with the red dye eosin. Granulocytes in general were described several decades earlier.
  • The hypereosinophilic syndrome was first described in 1968. [3]

Classification

Pathophysiology

  • Eosinophilia is defined by blood eosinophil count > 500/microL.
  • The pathogenesis is variable. Eosinophila can be caused by a proliferative neoplasm (as in eosinophilic leukemia), or as a reaction to another process (parasitic infection, drug reaction, solid tumor) that causes elevated levels in cytokines that promote eosinophil maturation in the bone marrow, or it may be idiopathic.

Causes

  • Eosinophilia can be caused by numerous different processes listed above.

Differentiating eosinophilia from other Diseases

  • If the eosinophil count is elevated, eosinophilia is present by definition. Care should be taken to discover the correct cause for the eosinophilia.

Epidemiology and Demographics

  • Eosinophilia is not a specific disease entity, epidemiologic numbers are availble for major causes of eosinophilia
  • Hypereosinophilic syndromes are extremely rare, estimated at 0.36 to 6.3 people per 100000 in the US. [1] Adults are most commonly affected, however children and the elderly can be affected as well.

Risk Factors

  • Common risk factors in the development of eosinophilia are allergies and parasitic infections. Eosinophilia is most commonly associated with allergic processes in developed countries and with parasitic infections in developing countries.

Natural History, Complications and Prognosis

  • Highly variable based on the underlying etiology.
  • The diseases eosinophilia can be associated with have a wide range of natural histories and prognoses.
  • An asthmatic patient with eosinophilia has a very different prognosis than a cancer patient with eosinophilia
  • Hypereosinophilic syndromes have a poor prognosis and high mortality, mostly from the cardiac effects of hypereosinophilia

Diagnosis

Diagnostic Criteria

  • The diagnosis of eosinophilia is made when the peripheral blood eosinophil count is greater than 500 cells/microL.
  • Hypereosinophilic syndrome usually has eosinphil counts greater than 1500 cells/microL. Hypereosinophilic syndrome also requires the presence of organ dysfunction that is caused by the eosinophils and cannot be explained by another disease process [1][4].

Symptoms

  • Symptoms seen in eosinophilia are highly variable and reflect the underlying disease.
  • Hypereosinophilia can cause symptoms due to the release of destructive compounds from eosinophils. [1][3][4] Symptoms attributable to the elevated eosinophil count include:
    • Dermatologic manifestations insluding rash, urticaria
    • Muscle and joint pains
    • Heart failure and endocardial fibrosis
    • Cough and shortness of breath
    • Thrombotic and embolic events
    • Encephalopathy or neuropsychiatric disturbances
    • Peripheral neuropathies
    • Abdominal pain, nausea/vomiting, diarrhea, weight loss
    • Any organ can be affected by hypereosinophilia and manifestations are variable

Physical Examination

  • Physical exam findings in eosinophilia are highly variable and reflect the underlying disease.
  • Physical exam findings in a hypereosinophilic syndrome are also highly variable, since the disease can affect any organ system. Possible manifestations include:
    • Signs of volume overload related to heart failure: peripheral edema, pulmonary edema, engorged neck veins, etc.
    • Rash, skin ulcerations, lichenification
    • Altered mental status
    • Respiratory distress

Laboratory Findings

  • There are no specific laboratory findings associated with eosinophilia aside from the elevated eosinophil count.
  • Anemia and thrombocytopenia or thrombocytosis may be seen if the eosinophilia is related to a clonal proliferative process in the bone marrow. [4]

Imaging Findings

  • There are no imaging findings associated with eosinophilia unless it is secondary to a disease process that causes imaging findings.

Treatment

Medical Therapy

  • Medical treatment for eosinophilia should be directed at the underlying cause (for example treating parasitic infection or malignancy).
  • Eosinophilia without evidence of organ dysfunction may be observed with monitoring for evidence of organ involvement.
  • Treatment of hypereosinophilic syndrome has a number of options including corticosteroids, hydroxyurea, interferon-alpha, imatinib and other tyrosine kinase inhibitors, IL-5 antibodies, and other cytotoxic and immunomodulatory agents. [1][4] [5]

Surgery

  • Surgery may be part of the treatment for certain causes of eosinophilia, such as solid organ malignancies. However most conditions associated with eosinophilia are not treated surgically.

Prevention

  • There are no primary preventive measures available for eosinophilia.
  • Primary prevention should be targeted as specific disease entities.

References

  1. 1.0 1.1 1.2 1.3 1.4 National Institute of Allergy and Infectious Disease, Hypereosinophilic Syndrome. http://www.niaid.nih.gov/topics/EosinophilicDisorders/Pages/Hyper.aspx
  2. Kay AB. The early history of the eosinophil. Clin Exp Allergy. 2015 Mar;45(3):575-82.
  3. 3.0 3.1 3.2 Brito-Babapulle. The Eosinophilias including the Hypereosinophilic Syndrome. British Journal of Hematology (2003) 121(3):203-223.
  4. 4.0 4.1 4.2 4.3 Cogan and Roufosse. Clinical Management of the Hypereosinophilic Syndromes. Expert Reviews in Hematology 5(3) 275-290 (2012).
  5. Ogbogu et al. Hypereosinophilic syndrome: A multicenter, retrospective analysis of clinical characteristics and response to therapy. Journal of Allergy and Clinical Immunology (2009) 124(6):1319–1325